An interventional study of optiflow in Apnea, Postanesthetic, Desaturation of Blood and Apnea, sponsored by University Hospital, Caen. Completed at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-18.
Sponsored by University Hospital, Caen · Not applicable, Interventional, and Treatment
Suspension laryngoscopy is realised during apnea. In effect, surgeons are in the mouth of the patient and we can't have access at the aiways.
So investigators like to use a Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) to increase time of apnea and decrease the impact of oxygen desaturation.
1,423 studies on the registry are indexed under Apnea; 160 are open to participants now.
This study's enrollment of 80 is above the median of 51 across 966 interventional studies indexed under Apnea.
Browse Apnea studies →University Hospital, Caen is the lead sponsor of 505 studies on the registry; 80 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
apnea without oxygenation like usual traitement
optiflow oxygenation during apnea
Device: optiflow
we use Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (thrive-optiflow) during general anesthesia for suspension laryngoscopy
desaturation defined as the number of patient who presented at least one desaturation during suspension laryngoscopy
the number of patient who presented at least one desaturation during suspension laryngoscopy. An oxygen desaturation define like SpO2\<96%
Time frame: Two hours
hypoxemia (decrease the number of Hypoxemia event define like SpO2<90%)
Decrease the number of Hypoxemia event define like SpO2\<90%
Time frame: 2 hours
side effect
decrease the number of side effects
Time frame: 2 hours
time of apnea
increase time of apnea with THRIVE
Time frame: 2 hours
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Caen